



07-11-06

AT
#

Express Mail No. EV 535 903 614 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bennett et al.

Confirmation No.: 6892

Application No.: 09/642,557

Group Art Unit: 1626

Filed: August 18, 2000

Examiner: Stockton, Laura

For: PYRAZOLOANTHRONE AND
DERIVATIVES THEREOF AS
JNK INHIBITORS AND
COMPOSITIONS AND
METHODS RELATED THERETO

Attorney Docket No.: 10624-046-999
(CAM: 700755-999045)

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Signal Pharmaceuticals, LLC is the assignee of the entire right, title and interest in and to U.S. Application No. 10/395,810 (the "'810 application") by virtue of an assignment from the inventors to Signal Pharmaceuticals, LLC recorded in the United States Patent and Trademark Office ("USPTO") on December 16, 2003 at Reel 014806 / Frame 0852.

Signal Pharmaceuticals, LLC is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment from inventors to Signal Pharmaceuticals, Inc. recorded in the USPTO on March 21, 2001 at Reel 011659 / Frame 0845 and a conversion from "Inc." to "LLC" recorded in the USPTO on January 14, 2005 at Reel 016154 / Frame 0774.

Signal Pharmaceuticals, LLC hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the patent issuing from the '810 application, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent issuing from the '810 application.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of the patent issuing from the '810 application in the event that the patent issuing from the '810 application later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

A fee of \$130.00 is believed due under 37 C.F.R. 1.20(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Date July 10, 2006

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)
JONES DAY
222 East 41st Street
New York, New York 10017
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, California 92130
(858) 314-1130